Cargando…
Potential new targets for drug development in severe asthma
In recent years there has been increasing recognition of varying asthma phenotypes that impact treatment response. This has led to the development of biological therapies targeting specific immune cells and cytokines in the inflammatory cascade. Currently, there are two primary asthma phenotypes, Ty...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203275/ https://www.ncbi.nlm.nih.gov/pubmed/30386455 http://dx.doi.org/10.1186/s40413-018-0208-1 |
_version_ | 1783365850998243328 |
---|---|
author | Zhu, Linda Ciaccio, Christina E. Casale, Thomas B. |
author_facet | Zhu, Linda Ciaccio, Christina E. Casale, Thomas B. |
author_sort | Zhu, Linda |
collection | PubMed |
description | In recent years there has been increasing recognition of varying asthma phenotypes that impact treatment response. This has led to the development of biological therapies targeting specific immune cells and cytokines in the inflammatory cascade. Currently, there are two primary asthma phenotypes, Type 2 hi and Type 2 lo, which are defined by eosinophilic and neutrophilic/pauci- granulocytic pattern of inflammation respectively. Most biologics focus on Type 2 hi asthma, including all four biologics approved for treatment of uncontrolled asthma in the United States — omalizumab, mepolizumab, reslizumab, and benralizumab. Potential new targets for drug development are being investigated, such as IL-13, IL-4α receptor, CRTH2, TSLP, IL-25, IL-13, IL-17A receptor, and CXCR2/IL-8. This review will discuss the role of these molecules on the inflammatory response in uncontrolled asthma and the emerging biologics that address them. Through the delineation of distinct immunological mechanisms in severe asthma, targeted biologics are promising new therapies that have the potential to improve asthma control and quality of life. |
format | Online Article Text |
id | pubmed-6203275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62032752018-11-01 Potential new targets for drug development in severe asthma Zhu, Linda Ciaccio, Christina E. Casale, Thomas B. World Allergy Organ J Review In recent years there has been increasing recognition of varying asthma phenotypes that impact treatment response. This has led to the development of biological therapies targeting specific immune cells and cytokines in the inflammatory cascade. Currently, there are two primary asthma phenotypes, Type 2 hi and Type 2 lo, which are defined by eosinophilic and neutrophilic/pauci- granulocytic pattern of inflammation respectively. Most biologics focus on Type 2 hi asthma, including all four biologics approved for treatment of uncontrolled asthma in the United States — omalizumab, mepolizumab, reslizumab, and benralizumab. Potential new targets for drug development are being investigated, such as IL-13, IL-4α receptor, CRTH2, TSLP, IL-25, IL-13, IL-17A receptor, and CXCR2/IL-8. This review will discuss the role of these molecules on the inflammatory response in uncontrolled asthma and the emerging biologics that address them. Through the delineation of distinct immunological mechanisms in severe asthma, targeted biologics are promising new therapies that have the potential to improve asthma control and quality of life. BioMed Central 2018-10-25 /pmc/articles/PMC6203275/ /pubmed/30386455 http://dx.doi.org/10.1186/s40413-018-0208-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Zhu, Linda Ciaccio, Christina E. Casale, Thomas B. Potential new targets for drug development in severe asthma |
title | Potential new targets for drug development in severe asthma |
title_full | Potential new targets for drug development in severe asthma |
title_fullStr | Potential new targets for drug development in severe asthma |
title_full_unstemmed | Potential new targets for drug development in severe asthma |
title_short | Potential new targets for drug development in severe asthma |
title_sort | potential new targets for drug development in severe asthma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203275/ https://www.ncbi.nlm.nih.gov/pubmed/30386455 http://dx.doi.org/10.1186/s40413-018-0208-1 |
work_keys_str_mv | AT zhulinda potentialnewtargetsfordrugdevelopmentinsevereasthma AT ciacciochristinae potentialnewtargetsfordrugdevelopmentinsevereasthma AT casalethomasb potentialnewtargetsfordrugdevelopmentinsevereasthma |